歷年活動 Events
2020 ATC抗體藥物研討會：後疫情時代抗體藥物 暨 新興抗體藥品開發策略 Antibody Therapeutics Conference 2020, Antibody Drug Development in the Post-COVID-19 Era and the Strategy of New Generation Antibody Drug Developmen
時間：2020年10月29日 (星期四)上午10:30
地點：國家生技研究園區C棟國際會議廳 (南港區研究院路一段130巷99號)
| Time | Activities | Speaker |
|---|---|---|
| 10:00-10:30 | Registration | |
| 10:30-10:35 | Welcome Remarks | Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
| 10:35-10:40 | Moderator | Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
| 10:40-11:10 | Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike | David D. Ho, M.D. (何大一院士), Director, Aaron Diamond AIDS Research Center, Columbia University |
| 11:10-11:40 | Medical requirements for COVID-19 treatments (Tentative) | Chang-Youh Tsai, M.D., Ph.D. (蔡長祐主任), Director, Division of Allergy, Immunology and Rheumatology, Taipei Veterans General Hospital |
| 11:40-12:10 | Using Monoclonal antibody for COVID-19 treatment — B Cell Antibody drug development platform (Tentative) | Kuan-Ying Arthur Huang, M.D., Ph.D. (黃冠穎醫師), Associate Professor, Chang Gung Medical Foundation |
| 12:10-12:15 | Group photo | |
| 12:15-13:20 | Lunch / 2nd meeting of the 3rd TAA Board of Directors | |
| 13:20-13:30 | 2nd meeting of the 3rd TAA General Assembly | |
| 13:30-13:35 | Moderator | Wei-Kuang Chi, Ph.D. (紀威光副執行長), Vice President, R&D, Development Center for Biotechology |
| 13:35-14:05 | Diagnostics of COVID-19 and invention of therapeutics mAb—monoclonal antibody (Tentative) | Han-Chung Wu , Ph.D. (吳漢忠主任), Director, BioTReC |
| 14:05-14:35 | CDMO supporting COVID-19 antibody drug development service (Tentative) | Lee-Cheng Liu, Ph.D. (劉理成總經理), President & CEO, EirGenix Inc. |
| 14:35-14:55 | Break | |
| 14:55-15:00 | Moderator | Shih-Chong Tsai, Ph.D. (蔡士昌所長), Executive Director, Institute of Biologics, Development Center for Biotechnology |
| 15:00-15:30 | Current development of Antibody drug conjugates (ADC) (Tentative) | Shih-Hsien Chuang, Ph.D. (莊士賢副所長), Deputy Director, Institute of Pharmaceutics, Development Center for Biotechnology |
| 15:30-16:00 | Proteomic profiling of antibody-drug conjugate biomarker panel for rational drug design | Sheeno Thyparambil, Ph.D., Senior Director R&D, mProbe Inc. |
| 16:00-16:05 | Closing Remarks | Chung-hsiun Wu, Ph.D. (吳忠勳理事長), Chairman of TAA |
